Literature DB >> 21768979

Dosing adjustments in postpartum patients maintained on buprenorphine or methadone.

Hendrée E Jones1, Rolley E Johnson, Kevin E O'Grady, Donald R Jasinski, Michelle Tuten, Lorraine Milio.   

Abstract

Scant scientific attention has been given to examining the need for agonist medication dose changes in the postpartum period. Study objectives were: 1) to determine the need for medication dose adjustments in participants stabilized on buprenorphine or methadone 3 weeks before and 4 weeks after delivery, and 2) to evaluate the need for methadone dose adjustments during the first 7 days in participants transferred from buprenorphine to methadone at 5 weeks postpartum. Participants were opioid-dependent pregnant women who had completed a randomized, double-blind, double-dummy, flexible dosing comparison of buprenorphine to methadone. Participants received a stable dose of methadone (N = 10) or buprenorphine (N = 8) before and 4 weeks after delivery. Buprenorphine-maintained participants were transferred to methadone at 5 weeks postpartum. There were no significant differences predelivery and/or postdelivery between the buprenorphine and methadone conditions in the mean ratings of dose adequacy, "liking," "hooked," and "craving" of heroin or cocaine. Patient response to the conversion from buprenorphine to methadone seems variable. Buprenorphine-maintained participants required dose changes postpartum only after they transferred to methadone. Regardless of type of medication, postpartum patients should be monitored for signs of overmedication.

Entities:  

Year:  2008        PMID: 21768979     DOI: 10.1097/ADM.0b013e31815ca2c6

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  7 in total

1.  Postpartum changes in methadone maintenance dose.

Authors:  Christine A Pace; Leah B Kaminetzky; Michael Winter; Debbie M Cheng; Kelley Saia; Jeffrey H Samet; Alexander Y Walley
Journal:  J Subst Abuse Treat       Date:  2014-05-02

2.  Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women.

Authors:  Marta Concheiro; Hendreé E Jones; Rolley E Johnson; Robin Choo; Marilyn A Huestis
Journal:  Ther Drug Monit       Date:  2011-10       Impact factor: 3.681

3.  Caring for Opioid-dependent Pregnant Women: Prenatal and Postpartum Care Considerations.

Authors:  Elizabeth E Krans; Gerald Cochran; Debra L Bogen
Journal:  Clin Obstet Gynecol       Date:  2015-06       Impact factor: 2.190

4.  Pharmacologic evidence to support clinical decision making for peripartum methadone treatment.

Authors:  D L Bogen; J M Perel; J C Helsel; B H Hanusa; M Romkes; T Nukui; C R Friedman; K L Wisner
Journal:  Psychopharmacology (Berl)       Date:  2012-08-25       Impact factor: 4.530

Review 5.  Treatment of opioid-dependent pregnant women: clinical and research issues.

Authors:  Hendree E Jones; Peter R Martin; Sarah H Heil; Karol Kaltenbach; Peter Selby; Mara G Coyle; Susan M Stine; Kevin E O'Grady; Amelia M Arria; Gabriele Fischer
Journal:  J Subst Abuse Treat       Date:  2008-01-14

6.  Maintenance agonist treatments for opiate-dependent pregnant women.

Authors:  Silvia Minozzi; Laura Amato; Shayesteh Jahanfar; Cristina Bellisario; Marica Ferri; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2020-11-09

Review 7.  Treating Women Who Are Pregnant and Parenting for Opioid Use Disorder and the Concurrent Care of Their Infants and Children: Literature Review to Support National Guidance.

Authors:  Stacey L Klaman; Krystyna Isaacs; Anne Leopold; Joseph Perpich; Susan Hayashi; Jeff Vender; Melinda Campopiano; Hendrée E Jones
Journal:  J Addict Med       Date:  2017 May/Jun       Impact factor: 3.702

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.